Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
19 sept. 2023 09h10 HE
|
Immix Biopharma, Inc.
Successful completion supports expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S.Plan for NXC-201 to expand into earlier lines of therapy, and beyond the...
U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma
23 août 2023 08h37 HE
|
Immix Biopharma, Inc.
FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified clinical testingWaiver of the Prescription Drug User Fee...
Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board
18 août 2023 09h20 HE
|
Immix Biopharma, Inc.
Dr. Landau joins the Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Memorial Sloan Kettering Cancer Center Dr. Landau is a recognized thought...
Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece)
16 août 2023 09h05 HE
|
Immix Biopharma, Inc.
LOS ANGELES, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology...
Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting
25 juil. 2023 08h42 HE
|
Immix Biopharma, Inc.
LOS ANGELES, July 25, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that updated NXC-201 relapsed/refractory...
Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial
17 juil. 2023 09h37 HE
|
Immix Biopharma, Inc.
Tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV...
Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
10 juil. 2023 09h47 HE
|
Immix Biopharma, Inc.
LOS ANGELES, July 10, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced the completion of its initial CAR-T...
Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial
26 juin 2023 09h49 HE
|
Immix Biopharma, Inc.
LOS ANGELES, June 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering cell therapies...
Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors
22 juin 2023 09h53 HE
|
Immix Biopharma, Inc.
Mr. Borkowski joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical and healthcare industry, including 7 years as Chief Financial Officer of...
Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors
20 juin 2023 09h45 HE
|
Immix Biopharma, Inc.
Mr. Cooper joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical industry, including 5 years as Chief Financial Officer of BioMarin...